Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists launch major study to unlock secrets of aging

NCT ID NCT02339012

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 01, 2026 · Updated 13 times

Summary

The GESTALT study is recruiting 900 adults aged 20 and older to investigate biomarkers related to aging. Participants will undergo a range of tests every two years, including blood work, imaging, and physical exams. The goal is to better understand how genetic and epigenetic changes contribute to aging and frailty.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could reveal key biological markers of aging, potentially guiding future treatments to improve health in older age.
What could go wrong
This is an observational study, not a treatment trial. It may not directly lead to therapies, and results may take years to translate into practical benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 900 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2015

Expected to finish

Dec 2099

An estimate. End dates often move.

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Healthy Volunteers, Non-Healthy/Non-Frail, Frail

Ages

20 to 120 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* Since the study of gene expression and epigenetic regulation are essential aims of GESTALT, all participants are required to consent to DNA/RNA testing and storage at all visits. Participants that refuse genetic testing and storage will not be eligible to participate or to continue to participate in the study. The criteria below for each group pertains only to the Screening and Baseline Visits, except where otherwise noted. If any of the conditions develop while the participant is in the study, the participant remains in the study. However, participants that develop severe cognitive problems and are diagnosed by the cognition group with dementia, will no longer be able to participate in the study. INCLUSION CRITERIA for the Healthy Group: * Age \>= 20 years of age. * Are willing to return every 2 years for study visit procedures. * Agree to genetic (DNA/RNA) sample collection, analysis, and storage. * Have good venous access for cytapheresis and are in good health as determined by the Apheresis Health History Questionnaire and are found eligible for apheresis (Apheresis Eligibility form). * Weigh \>= 110lbs and a body mass index (BMI) \< 30. * Do not have established genetic diseases such as sickle cell, hemochromatosis (iron overload), cystic fibrosis or Ehlers-Danlos syndrome (connective tissue disorder). * Do not have autoimmune diseases such as Hashimoto's thyroiditis, Myasthenia Gravis or Rheumatoid arthritis. * Report that they are able to perform daily self- care without assistance. * Report that they able to walk independently for at least 400 meters without assistance and without developing severe symptoms. * Report they are able to perform normal activities of daily living without shortness of breath (walking or climbing stairs) or other severe symptoms. * Do not have cognitive impairment based on mental status screening tests and evaluations and in the absence of any drug treatment. * Do not have a history of cardiovascular disease or cerebrovascular disease including angina (requiring treatment), myocardial infarction, congestive heart failure, uncontrolled hypertension, pacemaker, stroke, or transient ischemic attacks (TIA). * Do not have a history of diabetes (requiring any medical treatment other than diet and exercise) and their fasting Glucose is \<126 mg/dL. * Do not have active (any activity in the last 10 years) cancer, except for locally limited squamous and basal cell cancer. * Do not have clinically significant hormonal dysfunction (Self-reported or laboratory values out of range. Mild hypothyroidism in participants over 60 is not considered exclusion). * Do not have a history of neurological diseases or birth defects (other than minor anatomical abnormalities, which do not affect physical and/or cognitive function). * Do not have a history of kidney or liver disease (associated with reduced kidney or liver function). * Do not have a history of severe gastrointestinal (G.I.) diseases, with symptoms or requiring chronic treatment such as gastroesophageal reflux disease (GERD), Crohn s disease or ulcerative colitis. * Do not have a history of severe pulmonary disease such as chronic obstructive pulmonary disease (COPD) or asthma requiring continuous medication use. * Do not have muscle-skeletal conditions due to diseases or traumas (that cause pathological weakness and/or chronic pain). * Do not have a history of severe psychiatric conditions associated with behavioral problems or requiring absolute and continuous need for medical treatment. * Do not have any medical condition that requires absolute and continuous need for long term treatment with antibiotics, corticosteroids, immunosuppressors, H2 blockers and/or proton pump inhibitors, or pain medications. * Do not have a medical condition that requires the use of chronic anticoagulant medication such as Coumadin, heparin, or antiplatelet agents other than low dose aspirin. * Do not have important sensory deficits (legally blind and/or any condition that precludes the participant from being tested with standard neuropsychological tests or providing informed consent). * Are able to read and speak English. * Are able to understand the study risks and procedures, and consent to participate in the study. * Not currently pregnant or a nursing mother. * Do not currently smoke/vape and have not done so in the past 3 months. * Veins are adequate for cytapheresis. * No current illness that as judged by the study physician substantially increases the risks associated with cytapheresis (active infections, allergies, etc.). * No history of allergy to acid- citrate- dextrose (ACD) anticoagulant. * No history of an active bleeding disorder such as hemophilia or Von Willebrand disease. * No history of seizures within the last 3 months. * No history of Lyme disease, unless six weeks' post treatment and no new symptoms, of Chagas disease, Babesiosis, or Leishmanias. * Are not claustrophobic and are eligible to perform 3TMRI as per the MRI eligibility form. * Do not have hip or knee replacements or other medical conditions that prevent 3TMRI research scans from being performed. INCLUSION CRITERIA for the Non-Healthy-or-Frail and Frail groups: * Age \>= 20 years of age in the NHF group. * Age \>= 50 years of age in the F group. * Are willing to return every 2 years for study visit procedures. * Agree to genetic (DNA/RNA) sample collection, analysis, and storage. * Have good venous access for blood sampling. * Weigh \>= 110lbs and a body mass index (BMI) \<= 35. * Do not have established genetic diseases such as sickle cell, hemochromatosis (iron overload), cystic fibrosis or Ehlers-Danlos syndrome (connective tissue disorder). * Do not have important sensory deficits (legally blind and/or any condition that precludes the participant from being tested with standard neuropsychological tests or providing informed consent). * Are able to read and speak English. * Are able to understand the study risks and procedures, and consent to participate in the study. * Not currently pregnant or a nursing mother. * No current acute medical condition. * No history of an active bleeding disorder such as hemophilia or Von Willebrand disease. * No history of seizures within the last 3 months. * Are not claustrophobic and are eligible to perform 3TMRI as per the MRI eligibility form. * Do not have other medical conditions that prevent 3TMRI research scans from being performed. * Frail participants meet the A and B criteria as reported. * Not-Healthy-or-Frail participants will not be eligible for the Healthy group because of medical or functional problems and also do not meet the criteria for the Frail Group. Participant Exclusion Criteria: These criteria pertain to the Screening and Baseline Visits. If conditions considered as exclusion criteria for study entry develop any time after the Baseline evaluation, the participant remains in the study. Exclusion Criteria: * HIV virus infection (all groups). * Hepatitis B or C (all groups). * Active syphilis, gonorrhea or TB requiring treatment (all groups). * WBC \<3,000 or \> 12,000/k/microL (only Healthy group). * Platelets \< 100,000 or \>600,000 k/ microL (only Healthy group). * Hemoglobin \< 11.0 gm/dL in women and \< 12.0 gm/dL in men (only Healthy group). * GFR \<50 mL/min/1.73 m\^2 (only Healthy group) * GFR \<= to 30 (only non-Healthy-or-Frail group or Frail group) * Bilirubin \> 1.5 mg/dl (unless higher levels can be ascribed to Gilbert's disease (only Healthy group). * ALT, AST, or alkaline phosphatase twice the normal serum concentration (only Healthy group). * Corrected calcium \< 8.5 or \> 10.7 mg/dl (all groups). * Albumin \< 3.1 g/dl (only Healthy group). * Cholesterol, LDL and/or Triglycerides \>1.5x normal (only Healthy group). * Positive Urine Drug Screen (unless taking prescribed medication and at the discretion of the PI) (all groups). * Currently pregnant or a nursing mother (all groups). Furthermore, if the participant is found eligible at Screening and Baseline but fails a urine drug screen (unless taking a prescribed medication and at the discretion of the PI) at any of the subsequent visits, the participant will be asked to return to repeat the test and if positive, will no longer be eligible to participate in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FRAIL are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • National Institute of Aging, Clinical Research Unit

    RECRUITING

    Baltimore, Maryland, 21224, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.